Posted Sep. 29, 2012 at 9:15 a.m.

Premium Lock Study: GSK's melanoma drug combination slows cancer progress

Published: 2012-09-29 09:15:43
Updated: 2012-09-29 09:15:43

Cancer research Cancer research

Patients taking Glaxo's dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part of the second of three phases of human testing usually required by regulators....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll